Developer docs
API playgroundTry for free, no card

Search company profiles

Cognoa

Full company profile

uuid0000m2j

Namestring
Cognoa
Legal namestring
Cognoa, Inc.
Websiteurl
cognoa.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Cognoa is a Palo Alto-based pediatric behavioral health company that has built Canvas Dx, the first and only FDA-authorized AI-powered diagnostic aid for autism spectrum disorder in children ages 1.5 to 6 years. The system combines three data modalities — a caregiver-completed mobile questionnaire, a clinician-completed questionnaire, and computer-vision analysis of short home videos of the child — into a single diagnostic prediction with reported 95% sensitivity, 95% specificity, 97% NPV, and 95% PPV validated across diverse demographic strata. The AI includes a Responsible AI framework with an "Indeterminate" abstention outcome to reduce misclassification, and was developed from research originating at Harvard Medical School's Center for Biomedical Informatics under founder Dr. Dennis Wall PhD.

Cognoa monetizes Canvas Dx primarily through insurance reimbursement — the product is covered by Highmark commercial plans and has secured its first state Medicaid coverage in Wyoming — and supplements this with a wholly-owned California telemedicine subsidiary, Cognoa Clinical, which provides direct-pay diagnostic evaluations (HSA, FSA, cash) to families. Distribution runs through a clinical partner network spanning practices in California, Montana, Nevada, Pennsylvania, Virginia, New Jersey, Delaware, and Mississippi, alongside flagship enterprise relationships including a 2026 strategic partnership with Catalight Group (15,000 practitioners, 25,000 patients annually) and an exclusive international distribution partnership with The Ability Center covering Saudi Arabia and Arabic-speaking populations.

The company was founded in 2013 and has raised approximately $127M across four funding rounds led in multiple instances by Morningside. It operates with an 11-50 person headcount under CEO Dr. Sharief Taraman, a pediatric neurologist, and a leadership team that includes a dedicated Chief AI Officer (Halim Abbas) and a VP of Regulatory and Quality Affairs, reflecting the heavy regulatory and clinical-validation orientation of the business model.

Short descriptiontext

Cognoa is a Palo Alto-based pediatric behavioral health company that developed Canvas Dx, the first FDA-authorized AI diagnostic for autism in children ages 1.5 to 6 years. It sells through insurance reimbursement, a direct-pay California telemedicine subsidiary (Cognoa Clinical), and clinical and international distribution partners including Catalight Group and The Ability Center.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNewport Beach, United States
HQ citystring
Newport Beach
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI autism diagnostics, pediatric behavioral health, FDA-authorized diagnostics, autism spectrum disorder, digital health platform
Industry3 codes
PRIMARYHLACANAL
Pediatrics & Adolescent Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYEDAKAKAA
Autism Diagnostic & Educational Assessment Services
Education/Special Education & Learning Support Services/Autism Support Services (Educational)
SECONDARYHLALAEAJ
Neurodevelopmental & Behavioral Therapy Platforms (ADHD/Autism/Behavioral Coaching)
Healthcare & Life Sciences/Telehealth Platforms/Behavioral & Mental Health Teletherapy Platforms
NAICS code2 codes
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories62151
SIC code2 codes
  • Services-Medical Laboratories8071
  • Services-Prepackaged Software7372
Product category
AI-powered autism diagnostics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Diagnostic Testing Reimbursement
TypeSubscription Recurring
Description

Canvas Dx is reimbursed by health insurance providers including Highmark commercial plans and Medicaid programs. Healthcare providers bill for the diagnostic assessment through standard medical billing codes.

cognoa.com
2Direct Patient Services (Cognoa Clinical)
TypeProfessional Services
Description

Cognoa Clinical provides direct autism diagnostic evaluations to families in California via telemedicine, accepting HSA, FSA, and cash payments. This clinic-based service generates direct revenue from families without insurance coverage.

cognoa.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
Pricing details2 tiers
1Insurance-reimbursed diagnostic testing
ModelSubscriptionBilling cadenceMulti-year contract
Notes

Canvas Dx is covered by Highmark commercial insurance plans and Medicaid programs. Providers bill through standard medical billing codes. Specific patient out-of-pocket costs vary by insurance plan.

cognoa.com
2Direct pay clinical service (Cognoa Clinical)
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Cognoa Clinical in California accepts HSA, FSA, and direct cash payment. No specific pricing publicly listed.

cognoa.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Canvas Dx
Description

FDA-authorized AI-powered diagnostic solution for autism spectrum disorder in children ages 1.5 to 6 years, designed to diagnose or rule out autism within days rather than months.

cognoa.com
Core offering1 text field

Cognoa develops Canvas Dx, the first and only FDA-authorized AI-powered diagnostic solution for autism spectrum disorder in children ages 1.5 to 6 years. The platform combines caregiver questionnaires, clinician questionnaires, and AI analysis of home-recorded videos of child behavior to deliver a diagnostic prediction within days rather than months. Cognoa also operates Cognoa Clinical, a California-based telemedicine service that delivers the Canvas Dx assessment directly to families.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 95% sensitivity and 95% specificity in detecting or ruling out autism
+4 more records
Product overview1 text field

Cognoa is an early childhood development and pediatric behavioral health company offering digital diagnostics and therapeutics. The primary product is Canvas Dx, an FDA-authorized AI diagnostic system for autism detection in young children. Canvas Dx is supplemented by Cognoa Clinical, a telemedicine service providing direct patient assessments. The company operates a web-based clinical portal for providers and a mobile app for caregivers, with the AI combining multiple data inputs (videos, questionnaires) to produce diagnostic predictions.

Product and service2 records
1Canvas Dx
CategoryAI diagnostic software
Description

FDA-authorized AI-powered diagnostic solution that enables clinicians to diagnose or rule out autism in children ages 1.5 to 6 years within days. Combines caregiver questionnaires, clinician questionnaires, and analysis of home videos to generate diagnostic predictions with 95% sensitivity and 95% specificity. Prescription-based and reimbursed by Highmark and Medicaid programs.

2Cognoa Clinical
CategoryTelemedicine diagnostic service
Description

Telemedicine-based autism assessment service combining Canvas Dx with live virtual appointments with autism specialists. Available to families with children located in California; accepts HSA, FSA, and cash payments. Includes online intake, guided video recording, expert review, and telehealth visits.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-21
Description

Strategic partnership connecting early autism diagnosis with high-quality, outcomes-driven treatment services. Combines Cognoa's FDA-authorized Canvas Dx diagnostic tool with Catalight's network of 15,000 practitioners serving 25,000 patients annually. Partnership aims to place patients into care within 10 business days of assessment, addressing the 12-24 month wait times that currently plague the industry. Catalight has achieved 30% cost reductions through value-based care agreements.

2The Ability Center
Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-01-13
Description

Exclusive distribution partnership making Canvas Dx available in Saudi Arabia for children 18 to 72 months with developmental delay concerns. The Ability Center serves as the exclusive partner for the Middle East region, expanding access for Arabic-speaking families. Cognoa also aims to expand access for Arabic-speaking families in the US through this partnership.

prnewswire.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

EarliTec has FDA clearance for an AI-enabled eye-tracking diagnostic aid for autism (EarliPoint) in young children, making it the closest direct competitor to Cognoa's Canvas Dx in pediatric AI autism diagnostics. Both companies target primary care clinicians with FDA-authorized AI diagnostic tools aimed at reducing autism waitlists.

TypeDirect peer
Description

Akili develops FDA-authorized digital therapeutics (EndeavorRx) for pediatric ADHD, directly adjacent to Cognoa's pediatric neurodevelopmental focus. Both companies are SaMD players targeting pediatric behavioral health with AI/software-driven assessments and treatments prescribed through clinicians.

TypeEmerging player
Description

Hazel Health provides telehealth-based mental health services in K-12 schools and at home, addressing pediatric mental and behavioral health needs. Like Cognoa, it focuses on expanding access to developmental and behavioral care for children and serves as a complementary channel for early intervention.

TypeEmerging player
Description

Limbic applies AI to mental health care navigation and patient engagement, intersecting with Cognoa's AI-driven behavioral health mission. Both companies target improvements in access, triage, and outcomes in behavioral health through AI-enabled tools.

TypeBroad incumbent
Description

Lyra Health is a larger incumbent mental health platform offering therapy, coaching, and medication management to enterprise clients. While broader than Cognoa, it represents an established player in employer- and payer-funded behavioral health with similar reimbursement strategies.

TypeEmerging player
Description

Creyos (formerly Cambridge Brain Sciences) offers AI-driven cognitive and behavioral health assessments used by clinicians, overlapping with Cognoa's diagnostic positioning in pediatric behavioral health. Both companies apply validated digital assessments to support earlier clinical decision-making.

TypeEmerging player
Description

Brightline is a pediatric behavioral health company offering virtual therapy and assessment services for children and adolescents, overlapping with Cognoa's family-facing pediatric behavioral health mission. Both serve families seeking earlier intervention and digital-first care delivery.

TypeBroad incumbent
Description

Spring Health is a broader incumbent precision mental health platform serving employers and payers with AI-driven care matching. It represents the kind of scaled, payer-funded behavioral health platform that Cognoa's value-based autism pathway partnerships could evolve toward.

TypeDirect peer
Description

Behavior Imaging offers remote autism assessment platforms (NODA) that enable caregivers to upload videos for specialist review, closely mirroring Cognoa's home-video-based AI analysis. Both target schools, healthcare providers, and families seeking earlier autism evaluations.

TypeOthers
Description

Catalight is both a strategic partner and a meaningful adjacent player in the autism care ecosystem, operating a network of 15,000 practitioners serving 25,000 patients annually. While not a diagnostic competitor, it sets the operational benchmark for scaled, value-based autism care delivery that Cognoa plugs into.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cognoa

AI-powered autism diagnosticscognoa.com

Cognoa is a Palo Alto-based pediatric behavioral health company that developed Canvas Dx, the first FDA-authorized AI diagnostic for autism in children ages 1.5 to 6 years. It sells through insurance reimbursement, a direct-pay California telemedicine subsidiary (Cognoa Clinical), and clinical and international distribution partners including Catalight Group and The Ability Center.

What Cognoa does

Cognoa is a Palo Alto-based pediatric behavioral health company that has built Canvas Dx, the first and only FDA-authorized AI-powered diagnostic aid for autism spectrum disorder in children ages 1.5 to 6 years. The system combines three data modalities — a caregiver-completed mobile questionnaire, a clinician-completed questionnaire, and computer-vision analysis of short home videos of the child — into a single diagnostic prediction with reported 95% sensitivity, 95% specificity, 97% NPV, and 95% PPV validated across diverse demographic strata. The AI includes a Responsible AI framework with an "Indeterminate" abstention outcome to reduce misclassification, and was developed from research originating at Harvard Medical School's Center for Biomedical Informatics under founder Dr. Dennis Wall PhD.

Cognoa monetizes Canvas Dx primarily through insurance reimbursement — the product is covered by Highmark commercial plans and has secured its first state Medicaid coverage in Wyoming — and supplements this with a wholly-owned California telemedicine subsidiary, Cognoa Clinical, which provides direct-pay diagnostic evaluations (HSA, FSA, cash) to families. Distribution runs through a clinical partner network spanning practices in California, Montana, Nevada, Pennsylvania, Virginia, New Jersey, Delaware, and Mississippi, alongside flagship enterprise relationships including a 2026 strategic partnership with Catalight Group (15,000 practitioners, 25,000 patients annually) and an exclusive international distribution partnership with The Ability Center covering Saudi Arabia and Arabic-speaking populations.

The company was founded in 2013 and has raised approximately $127M across four funding rounds led in multiple instances by Morningside. It operates with an 11-50 person headcount under CEO Dr. Sharief Taraman, a pediatric neurologist, and a leadership team that includes a dedicated Chief AI Officer (Halim Abbas) and a VP of Regulatory and Quality Affairs, reflecting the heavy regulatory and clinical-validation orientation of the business model.

Cognoa firmographics

Firmographics
Name
Cognoa
Legal name
Cognoa, Inc.
Website
https://cognoa.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Cognoa is a Palo Alto-based pediatric behavioral health company that developed Canvas Dx, the first FDA-authorized AI diagnostic for autism in children ages 1.5 to 6 years. It sells through insurance reimbursement, a direct-pay California telemedicine subsidiary (Cognoa Clinical), and clinical and international distribution partners including Catalight Group and The Ability Center.
Ownership category
akta.pro rank

Cognoa industry classification

Industry
Product category
AI-powered autism diagnostics
NAICS
Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)
SIC
Services-Medical Laboratories (8071), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLACANAL
Pediatrics & Adolescent Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYEDAKAKAA
Autism Diagnostic & Educational Assessment Services
Education/Special Education & Learning Support Services/Autism Support Services (Educational)
SECONDARYHLALAEAJ
Neurodevelopmental & Behavioral Therapy Platforms (ADHD/Autism/Behavioral Coaching)
Healthcare & Life Sciences/Telehealth Platforms/Behavioral & Mental Health Teletherapy Platforms

Keywords

  • AI autism diagnostics
  • Pediatric behavioral health
  • FDA-authorized diagnostics
  • Autism spectrum disorder
  • Digital health platform

Where Cognoa is headquartered

Location

Headquarters

HQ city
Newport Beach
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Cognoa business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

  1. Diagnostic Testing Reimbursement: Canvas Dx is reimbursed by health insurance providers including Highmark commercial plans and Medicaid programs. Healthcare providers bill for the diagnostic assessment through standard medical billing codes.
  2. Direct Patient Services (Cognoa Clinical): Cognoa Clinical provides direct autism diagnostic evaluations to families in California via telemedicine, accepting HSA, FSA, and cash payments. This clinic-based service generates direct revenue from families without insurance coverage.

Pricing tiers

ModelBillingPrice
SubscriptionMulti-year contractInsurance-reimbursed diagnostic testing
One time/ perpetual licensePay-as-you-goDirect pay clinical service (Cognoa Clinical)

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Cognoa product offering

Product offering

Core offering

Cognoa develops Canvas Dx, the first and only FDA-authorized AI-powered diagnostic solution for autism spectrum disorder in children ages 1.5 to 6 years. The platform combines caregiver questionnaires, clinician questionnaires, and AI analysis of home-recorded videos of child behavior to deliver a diagnostic prediction within days rather than months. Cognoa also operates Cognoa Clinical, a California-based telemedicine service that delivers the Canvas Dx assessment directly to families.

Product overview

Cognoa is an early childhood development and pediatric behavioral health company offering digital diagnostics and therapeutics. The primary product is Canvas Dx, an FDA-authorized AI diagnostic system for autism detection in young children. Canvas Dx is supplemented by Cognoa Clinical, a telemedicine service providing direct patient assessments. The company operates a web-based clinical portal for providers and a mobile app for caregivers, with the AI combining multiple data inputs (videos, questionnaires) to produce diagnostic predictions.

Differentiator

Problem solved

Functional benefit

Brands

  • Canvas Dx: FDA-authorized AI-powered diagnostic solution for autism spectrum disorder in children ages 1.5 to 6 years, designed to diagnose or rule out autism within days rather than months.

Products and services

  • Canvas Dx FDA-authorized AI-powered diagnostic solution that enables clinicians to diagnose or rule out autism in children ages 1.5 to 6 years within days. Combines caregiver questionnaires, clinician questionnaires, and analysis of home videos to generate diagnostic predictions with 95% sensitivity and 95% specificity. Prescription-based and reimbursed by Highmark and Medicaid programs.
  • Cognoa Clinical Telemedicine-based autism assessment service combining Canvas Dx with live virtual appointments with autism specialists. Available to families with children located in California; accepts HSA, FSA, and cash payments. Includes online intake, guided video recording, expert review, and telehealth visits.

Quantifiable outcome

  • 95% sensitivity and 95% specificity in detecting or ruling out autism
  • +4 more outcomes

Companies that use Cognoa

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Cognoa technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature5 records

Cognoa partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core and flagship.

  • Catalight GroupcoreStrategic or Co-development Partner · 21 April 2026Strategic partnership connecting early autism diagnosis with high-quality, outcomes-driven treatment services. Combines Cognoa's FDA-authorized Canvas Dx diagnostic tool with Catalight's network of 15,000 practitioners serving 25,000 patients annually. Partnership aims to place patients into care within 10 business days of assessment, addressing the 12-24 month wait times that currently plague the industry. Catalight has achieved 30% cost reductions through value-based care agreements.
  • The Ability CenterflagshipChannel Partner/ Reseller/ Distributor · 13 January 2026Exclusive distribution partnership making Canvas Dx available in Saudi Arabia for children 18 to 72 months with developmental delay concerns. The Ability Center serves as the exclusive partner for the Middle East region, expanding access for Arabic-speaking families. Cognoa also aims to expand access for Arabic-speaking families in the US through this partnership.

Scale indicators4 records

Recent moves6 records

Expansion highlights7 records

Cognoa competitors and assessment

Company assessment

Direct peers

  • EarliTec Diagnostics: EarliTec has FDA clearance for an AI-enabled eye-tracking diagnostic aid for autism (EarliPoint) in young children, making it the closest direct competitor to Cognoa's Canvas Dx in pediatric AI autism diagnostics. Both companies target primary care clinicians with FDA-authorized AI diagnostic tools aimed at reducing autism waitlists.
  • Akili Interactive: Akili develops FDA-authorized digital therapeutics (EndeavorRx) for pediatric ADHD, directly adjacent to Cognoa's pediatric neurodevelopmental focus. Both companies are SaMD players targeting pediatric behavioral health with AI/software-driven assessments and treatments prescribed through clinicians.
  • Behavior Imaging Solutions: Behavior Imaging offers remote autism assessment platforms (NODA) that enable caregivers to upload videos for specialist review, closely mirroring Cognoa's home-video-based AI analysis. Both target schools, healthcare providers, and families seeking earlier autism evaluations.

Emerging players

  • Hazel Health: Hazel Health provides telehealth-based mental health services in K-12 schools and at home, addressing pediatric mental and behavioral health needs. Like Cognoa, it focuses on expanding access to developmental and behavioral care for children and serves as a complementary channel for early intervention.
  • Limbic: Limbic applies AI to mental health care navigation and patient engagement, intersecting with Cognoa's AI-driven behavioral health mission. Both companies target improvements in access, triage, and outcomes in behavioral health through AI-enabled tools.
  • Creyos: Creyos (formerly Cambridge Brain Sciences) offers AI-driven cognitive and behavioral health assessments used by clinicians, overlapping with Cognoa's diagnostic positioning in pediatric behavioral health. Both companies apply validated digital assessments to support earlier clinical decision-making.
  • Brightline Health: Brightline is a pediatric behavioral health company offering virtual therapy and assessment services for children and adolescents, overlapping with Cognoa's family-facing pediatric behavioral health mission. Both serve families seeking earlier intervention and digital-first care delivery.

Broad incumbents

  • Lyra Health: Lyra Health is a larger incumbent mental health platform offering therapy, coaching, and medication management to enterprise clients. While broader than Cognoa, it represents an established player in employer- and payer-funded behavioral health with similar reimbursement strategies.
  • Spring Health: Spring Health is a broader incumbent precision mental health platform serving employers and payers with AI-driven care matching. It represents the kind of scaled, payer-funded behavioral health platform that Cognoa's value-based autism pathway partnerships could evolve toward.

Others

  • Catalight Group: Catalight is both a strategic partner and a meaningful adjacent player in the autism care ecosystem, operating a network of 15,000 practitioners serving 25,000 patients annually. While not a diagnostic competitor, it sets the operational benchmark for scaled, value-based autism care delivery that Cognoa plugs into.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Cognoa social profiles

Digital presence

Cognoa financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cognoa leadership team

Management profile

Number of profiles

Profiles6 records

Cognoa subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Cognoa funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cognoa M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cognoa

What does Cognoa do?

Cognoa develops Canvas Dx, the first and only FDA-authorized AI-powered diagnostic solution for autism spectrum disorder in children ages 1.5 to 6 years. The platform combines caregiver questionnaires, clinician questionnaires, and AI analysis of home-recorded videos of child behavior to deliver a diagnostic prediction within days rather than months. Cognoa also operates Cognoa Clinical, a California-based telemedicine service that delivers the Canvas Dx assessment directly to families.

Is Cognoa a public or private company?

Cognoa is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cognoa founded?

Cognoa was founded in 2013. It employs 11 to 50 people.

Where is Cognoa based?

Cognoa is headquartered in Newport Beach, United States, in the North America region.

How does Cognoa make money?

Two revenue lines are on record. Diagnostic Testing Reimbursement is the primary driver. The others are direct Patient Services (Cognoa Clinical).

Who are Cognoa's main competitors?

Direct peers on record are EarliTec Diagnostics, Akili Interactive and Behavior Imaging Solutions. Emerging players are Hazel Health, Limbic, Creyos and Brightline Health. Broad incumbents are Lyra Health and Spring Health. Catalight Group is listed as an others.

Does Cognoa have an API?

No public API is recorded for Cognoa.

What industry is Cognoa in?

Cognoa's product category is AI-powered autism diagnostics. Its primary akta.pro industry code is HLACANAL, Pediatrics & Adolescent Therapeutics (Digital), with a secondary code of EDAKAKAA, Autism Diagnostic & Educational Assessment Services. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Psychiatric TimesFacilitating Autism DiagnosisAI-based diagnostic tools are being explored to expedite autism spectrum disorder (ASD) diagnosis, which often occurs after age 4. The NODA system achieved 85% sensitivity and 94% specificity, while Cognoa's system showed up to 90% sensitivity and 83% specificity. These tools aim to shorten wait times and enable remote evaluations.BBCAutism: FDA don okay 'severe autism' detection device for babiesThe US FDA approved the Cognoa ASD Diagnosis Aid, a software tool to help detect severe autism in children aged 18 months to 5 years. The tool includes a mobile app, video analysis portal, and healthcare provider platform, and may return a positive or negative result, though it carries a small risk of false results.AijournCollaboration Connects Early Autism Diagnosis with High-Quality, Outcomes-Driven Care Amid Industry-Wide Access IssuesThe nonprofit Catalight Group and pediatric behavioral health company Cognoa have partnered to create a connected pathway from early autism diagnosis to treatment services, combining Cognoa's FDA-authorized AI diagnostic tool Canvas Dx with Catalight's network of 15,000 practitioners serving 25,000 patients annually. The collaboration aims to address severe workforce shortages that currently leave families waiting 12-24 months for an autism evaluation, with the partnership promising to place patients into care within 10 business days of assessment. Catalight has achieved 30% cost reductions through value-based care agreements and reports that lower-hour, individualized care produces outcomes equal to or better than traditional high-hour models.PR NewswireCollaboration Connects Early Autism Diagnosis with High-Quality, Outcomes-Driven Care Amid Industry-Wide Access IssuesThe nonprofit Catalight Group and Cognoa have announced a strategic partnership to connect early autism diagnostic evaluation with evidence-based treatment services, addressing the growing gap between demand and available qualified professionals in the United States. Cognoa's Canvas Dx, the first FDA-authorized AI diagnostic tool for autism in children as young as 18 months, enables diagnosis in days compared to the typical 12–24 month wait, with Catalight able to place patients into care within 10 business days. The collaboration aims to expand equitable, value-based autism care through a continuous pathway from diagnosis to treatment, with the combined reach of over 15,000 practitioners serving more than 25,000 patients annually.Nova One AdvisorDigital Brain Health Market Size to Worth Around USD 473.70 Bn by 2035The global digital brain health market is projected to grow from USD 232.59 billion in 2025 to USD 473.70 billion by 2035, at a CAGR of 7.37%, driven by rising neurological disorders, AI integration, and mental health awareness. Recent industry developments include product launches by Neurotrack, FDA breakthrough designation for Cognoa's autism diagnostic AI platform, and clinic openings by Neuroglee Therapeutics. The market faces challenges including data privacy concerns and limited regulatory frameworks for digital mental health tools.NewswireWorld's First Chief AI Officer and Peak Performance Experts to Take Stage at Healthcare CX ConferenceLeague, an AI-driven healthcare CX platform, announced three keynote speakers for its invite-only League Connect 2026 conference in Palm Beach, focused on 'Peak Performance' in healthcare consumer experience. The keynote lineup includes Sol Rashidi, recognized as the world's first Chief AI Officer for enterprise who previously led over 200 AI deployments including IBM's Watson; Steven Kotler, a peak performance researcher whose work is used by the U.S. Navy SEALs and Google; and Marc Priestley, a former McLaren F1 senior mechanic. The conference will gather over 100 healthcare leaders from payer, provider, and technology organizations, with additional agenda speakers from BCBS, NHS, Cognoa, Caresource, and Google.PR NewswireAbility Center brings Cognoa's Canvas Dx to Saudi Arabia, giving families faster, more precise autism evaluations in early childhoodCognoa and The Ability Center announced the exclusive availability of Canvas Dx in Saudi Arabia, making the FDA-authorized AI-enabled pediatric autism diagnostic aid accessible to children 18 to 72 months with developmental delay concerns. Canvas Dx is the first FDA-authorized AI diagnostic tool for autism and is designed to help clinicians reach diagnostic clarity in weeks rather than months. Cognoa aims to expand access for Arabic-speaking families in the US and children in surrounding countries through this partnership.openPR.comChatbots for Mental Health and Therapy Market Report- Expansive Coverage on the Profit SourcesInsightAce Analytic released a market research report estimating the global chatbots for mental health and therapy market at $1.2 billion in 2024, projected to reach $2.1 billion by 2034 with a 6% CAGR. The report identifies key market drivers including advancements in ML and NLP algorithms, opportunities such as government funding and telehealth adoption, and challenges related to regulatory compliance and technology limitations in interpreting complex human emotions. Recent industry developments include partnerships between PayrollPlans, Woebot Health, and Curai Health, Biobeat's Epic EHR integration, and Cognoa's leadership expansion for its pediatric autism diagnostic tool.